OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy

Core Insights - The article discusses the past experiences with Advaxis, a company focused on Listeria-based immunotherapy, highlighting that initial hopes did not materialize into successful patient outcomes [1] Company Analysis - Advaxis was previously viewed with optimism regarding its immunotherapy approach, but the results did not meet expectations, indicating potential challenges in the biotech sector [1] Industry Context - The article emphasizes the importance of understanding the science behind biotech investments, suggesting that investors should conduct thorough due diligence to avoid pitfalls in this volatile industry [1]